EMA confirms positive benefit-risk for antidepressant Valdoxan/Thymanax (agomelatine)

View source ↗

Summary

The EMA confirms a positive benefit-risk profile for agomelatine (Valdoxan/Thymanax) as an antidepressant after evaluating available data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder

Drugs mentioned

• Thymanax (agomelatine)
• Valdoxan (agomelatine)